Hematology Oncology Research

Publications

Researchers within the UCLA Division of Hematology-Oncology routinely disseminate the findings of their impactful work through publications in top-tier journals. Keep up with their latest articles here.

June 2026

  1. Beumer A, Carlson M, Arcuri AL, Maues J, Cowden J, Walker S, Shanahan K, Collins JL, Veach AJ, Rugo HS, Burkard ME, Kalinsky KM, Bardia A, Lustberg MB, Papautsky EL, Roberson ML. A Patient-Led Survey of Antibody Drug Conjugate Usage and Dosing for People Living With Metastatic Breast Cancer. J Patient Exp. 2026 May 30;13:23743735261457837. doi: 10.1177/23743735261457837. PMID: 42227000; PMCID: PMC13222401.
  2. Arslan S, Cutler C, Alousi A, Hamadani M, Abhyankar SH, Pusic I, Ross M, Schiller G, Dash A, Liu W, Yu Y, Lekkerkerker A, Wong C, Peck MC. A Phase Ib Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2026 May 31:S2666-6367(26)00443-4. doi: 10.1016/j.jtct.2026.05.042. Epub ahead of print. PMID: 42225184.
  3. Wu YL, Hochmair M, Yang Y, Yang XN, Tsuboi M, Paz-Ares L, Yang JC, Wu L, Kim HR, Rieke DT, Johnson M, Besse B, Sharma N, Maeda P, Peterson P, Lin BK, Frimodt-Moller B, Goldman J, Drilon A; LIBRETTO-432 Trial Investigators. Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2026 May 31. doi: 10.1056/NEJMoa2602628. Epub ahead of print. PMID: 42223087.
  4. O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM; RASolute 302 Trial Investigators. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026 May 31. doi: 10.1056/NEJMoa2605555. Epub ahead of print. PMID: 42223072.
  5. Wang ES, Erba HP, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld LC, Balasubramanian SK, Guru Murthy GS, Rotta M, Palmisiano N, McCloskey J, Saliba AN, Khawandanah M, Madanat YF, Naqvi K, Qasrawi AH, Schiller GJ, Badar T, Gojo I, Yaghmour G, Osman D, Zhang H, Tian Y, Soifer HS, Riches M, Corum D, Leoni M, Fathi AT, Issa GC. Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia. Blood. 2026 Jun 2:blood.2026034043. doi: 10.1182/blood.2026034043. Epub ahead of print. PMID: 42227701.
  6. Nolin A, Brown MD, Thomas SM, Strickland KC, Bean S, Neff JL, Pothuri B, Moore KN, Mullen M, Clark LH, Konecny G, Jackson AL, Ko EM, Whitaker R, Linhart S, March L, Hacker K, Washington C, Thaker P, Maxwell GL, Berchuck A, Secord AA, Previs RA. Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study. Int J Gynecol Cancer. 2026 Apr 29;36(8):104727. doi: 10.1016/j.ijgc.2026.104727. Epub ahead of print. PMID: 42235254.
  7. Doroshow DB, Leal TA, Waqar SN, Borghaei H, Camidge DR, Dragnev KH, Edelman MJ, Gandara DR, Gerber DE, Gray JE, Hirsch FR, Husain H, Kozono DE, Leighl NB, Li BT, Mack PC, Neal JW, Paik PK, Patel SP, Riess JW, Redman MW, Reckamp KL. Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators. J Clin Oncol. 2026 Jun 3:JCO2501896. doi: 10.1200/JCO-25-01896. Epub ahead of print. PMID: 42234933.
  8. Huynh J, Eisenbud L, Gutierrez R, Chuang FL, Dichter D. Late Recognition of Glucose-6-Phosphate Dehydrogenase Deficiency in a 70-Year-Old Man: A Case Report. Cureus. 2026 May 4;18(5):e108227. doi: 10.7759/cureus.108227. PMID: 42245854; PMCID: PMC13231936.
  9. Kim HR, Oliva M, Salas S, Wong DJ, Even C, Kim JW, Kang M, Wu SY, Lauche O, Ahn MJ, Yang MH, Lien MY, Metcalf R, Clatot F, McGrath M, Webster M, Assaf JD, Rivas AS, Bernsdorf M, Billan S, Kaczmar J, Grose D, Jankowska P, Jelinek MJ, Ciuleanu TE, Vieira C, Dutcus C, Okpara CE, Wang G, Bidadi B, Gumuscu B, Harrington K. Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial. Eur J Cancer. 2026 May 22;243:116824. doi: 10.1016/j.ejca.2026.116824. Epub ahead of print. PMID: 42241967.
  10. Juarez Casillas JE, Nezafat M, Benitez CM, Rzechowski K, Kane N, Sjöstrand K, Anand A, Sonni I, Berenji GR, Duriseti S, Rettig MB, Nickols NG. Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases. PLoS One. 2026 Jun 5;21(6):e0349825. doi: 10.1371/journal.pone.0349825. PMID: 42247403; PMCID: PMC13240907.
  11. Kumar S, Benavides-Serrato A, Saunders JT, Nishimura RN, Gera JF. PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma. J Neurooncol. 2026 Jun 5;178(2):45. doi: 10.1007/s11060-026-05564-w. PMID: 42247073; PMCID: PMC13241469.
  12. Bansil S, Lai SY, Lo AE, Dietz R Jr, Reed JP. A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That Evolved From Myelodysplastic Neoplasm. Cureus. 2026 May 5;18(5):e108281. doi: 10.7759/cureus.108281. PMID: 42255780; PMCID: PMC13234569.
  13. Kirtane K, Niu J, Blumenschein G, Massarelli E, Hanna GJ, Lee S, Bishop MR, Konecny GE, Mao D, Zheng Y, Rodriguez K, Kim JJ, Williams C, Schweitzer C, Adhikary S, Jung AS, Klebanoff CA. A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial). Front Oncol. 2026 May 21;16:1809354. doi: 10.3389/fonc.2026.1809354. PMID: 42266673; PMCID: PMC13244869.
  14. Lim A, Peluso EM, Downs IA, Horwich BH, Velez-Velez MA, Lechner MG. Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1. JCEM Case Rep. 2026 Jun 9;4(7):luag112. doi: 10.1210/jcemcr/luag112. PMID: 42273283; PMCID: PMC13247532.
  15. Llovet JM, Mauro E, Rimassa L, Mazzaferro V, Pinter M, Kelley RK, Chan SL, Kulik L, Pillai A, Roberts L, Sangro B, Casanovas T, Kaplan DE, Vogel A, Yarchoan M, Finn RS, Meyer T, Singal AG. Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement. Nat Rev Clin Oncol. 2026 Jun 10. doi: 10.1038/s41571-026-01160-z. Epub ahead of print. PMID: 42270817.
  16. Keramida K, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Dent S, Drakaki A, Fuster JJ, Mamas MA, Okwuosa T, Scarfo L, Van Der Meer P, Yang EH, Lopez-Fernandez T. Sex Differences in Cancer and Cardiotoxicity: Mechanisms, Outcomes, and Clinical Implications Across Solid and Hematological Malignancies. Cancers (Basel). 2026 May 22;18(11):1677. doi: 10.3390/cancers18111677. PMID: 42279262.
  17. Aggarwal H, Gupta N, Sengupta A, Sarkar A, Mylavarapu S, Pires IS, Saha T, Sarkar B, Kulkarni A, Mahajan VS, Goyal L, Bardia A, Fahrner R, Gherardi E, Mashelkar R, Soon-Shiong P, Jang HL, Sengupta S. Activating a B cell immune response regresses immunologically cold tumours. Nat Nanotechnol. 2026 Jun 12. doi: 10.1038/s41565-026-02170-9. Epub ahead of print. PMID: 42286216.
  18. Wander SA, Weipert CM, Cabel L, Liao J, Zhang N, Safonov A, Bardia A, Razavi P. Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer. NPJ Breast Cancer. 2026 Jun 12. doi: 10.1038/s41523-026-00986-1. Epub ahead of print. PMID: 42286014.
  19. Mouabbi JA, Lipsyc-Sharf MD, Yan F. Practical approach to MRD testing in breast cancer: Q&A. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):11-15. PMID: 42283709.
  20. Lipsyc-Sharf MD. Interpreting MRD results and integrating assays into practice. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):7-11. PMID: 42283708.
  21. Mouabbi JA, Lipsyc-Sharf MD, Yan F. Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):1-16. PMID: 42283705.
  22. Zuckerman JE, Larson S, Abdelnour L. Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia. Kidney Med. 2026 May 12;8(7):101402. doi: 10.1016/j.xkme.2026.101402. PMID: 42290670; PMCID: PMC13254867.
  23. Bruyat D, Girard N, Heudel P, Penel N, Le Deley MC, Diallo I, Boher JM, Zemmour C, Chanez B, Madroszyk A, Gravis G, Billon E, Lisberg A, Collineau B, Beaufils M, Gonçalves A, Tejeda M, Chrétien AS, Rochigneux P. Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences. Cancer Commun (Lond). 2026 Jun 17;46:0035. doi: 10.34133/cancomm.0035. PMID: 42318065; PMCID: PMC13273061.
  24. Misic A, Ghanem G, Sadeghi S, Carroll M. Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology. Thromb J. 2026 Jun 19. doi: 10.1186/s12959-026-00887-0. Epub ahead of print. PMID: 42321799.
  25. Zheng S, Sullivan P, Vadehra K, Kim J, Levee A, Callahan R, Teshome M, Tseng CH, Bardia A, Kapoor NS. Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer. Breast Cancer Res Treat. 2026 Jun 22;217(3):57. doi: 10.1007/s10549-026-08009-0. PMID: 42329472.
  26. Ji J, Sedrak MS. Personalizing cancer care for older adults. J Gerontol A Biol Sci Med Sci. 2026 Jun 6;81(7):glag126. doi: 10.1093/gerona/glag126. PMID: 42329168; PMCID: PMC13284996.
  27. Olszewski AJ, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, Holmes H, McKinney MS, Woszczyk D, Giannopoulos K, Jurczak W, Jing J, Li D, Hamidi H, Penuel E, Janousek M, Wei MC, Batlevi C, Ead W, Sellam G, Horowitz NA. Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial. Blood Neoplasia. 2026 May 16;3(3):100248. doi: 10.1016/j.bneo.2026.100248. PMID: 42327599; PMCID: PMC13276744.
  28. Di Carlo D, Morsut L, McCain ML, Wright HJ, Abedi M, Yamada-Hunter SA, Zhang JZ, Backus K, Chung E, Wang Y, Rando TA, Cai L, Thomson M, Elowitz MB, Lee JK, Witte O. Mapping and engineering the human cell-cell interactome. Nat Biotechnol. 2026 Jun 23. doi: 10.1038/s41587-026-03177-2. Epub ahead of print. PMID: 42337362.
  29. Othus M, Truong TG, Sharon E, Kendra K, Grossmann K, Buchbinder E, Khushalani NI, Eroglu Z, Chandra S, Doolittle GC, Kirkwood JM, Ikeguchi A, Mihalcioiu C, Cowey CL, Reddy SA, Johnson DB, Taylor M, Sondak VK, Ribas A, Patel SP. Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy. JCO Oncol Pract. 2026 Jun 23:OP2501413. doi: 10.1200/OP-25-01413. Epub ahead of print. PMID: 42335437.
  30. Arzoo KK, Berkowitz MJ. Endometrial Serous Carcinoma Arising From Adenomyosis. Cureus. 2026 May 22;18(5):e109441. doi: 10.7759/cureus.109441. PMID: 42333330; PMCID: PMC13283456.
  31. Tsvetkova O, Gil TE, Kassir G, Castanon S, Kollapaneni SS, Han A, Park SJ, Li R, Velez MA, Lisberg AE. Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer. Future Oncol. 2026 Jun 25:1-16. doi: 10.1080/14796694.2026.2685854. Epub ahead of print. PMID: 42345080.
  32. Aziz N, Kim EY, Jamieson BD, Mimiaga MJ, Martinez J, Detels R. Case Report: A case of HIV seroconversion in a high-risk individual after 35 years of resistance with a CCR5Δ32 heterozygous genotype. Virus Res. 2026 Jun 24:199770. doi: 10.1016/j.virusres.2026.199770. Epub ahead of print. PMID: 42341881.
  33. Sedrak MS, Ramalingam SS, Sparano JA. "Protected time" for clinical investigators in medical oncology: The persistent gap between expectation and reality. Cancer. 2026 Jul 1;132(13):e70499. doi: 10.1002/cncr.70499. PMID: 42340000; PMCID: PMC13292070.
  34. Markosian C, Schiller GJ. The case for prospective MEN1 surveillance in the era of sequential menin inhibitor therapy. Leukemia. 2026 Jun 25. doi: 10.1038/s41375-026-03023-z. Epub ahead of print. PMID: 42350603.
  35. Abascal J, Dumitras C, Tran LM, Crosson W, Kahangi B, Oh M, Rennels A, Lim RJ, Jiang H, Reyimjan D, Coleman NJ, Perez-Reyes E, Chin S, Krysan K, Dubinett SM, Liu B, Salehi-Rad R. FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer. J Immunother Cancer. 2026 Jun 25;14(6):e014914. doi: 10.1136/jitc-2026-014914. PMID: 42350046.
  36. Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand RG, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine JP, Lin C, Kopmar NE, Tsai SB, O'Connor TE, Hilal T, Solh MM, Guzowski C, Tan V, Majhail NS, Battiwalla M, Malik SA, Mathews J, Shaughnessy PJ, Mountjoy L, Dykes KC, Logan AC, Schwartz MS, Connor MP, Wang J, Vasu S, Kumaran M, Hoeg RT, Tracy SI, Yalniz FF, Yaghmour G, Pullarkat VA, Cassaday RD, Leonard JT, Shah BD, Frey NV, Muffly LS, Aldoss I. Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL. Blood Adv. 2026 Jun 25:bloodadvances.2026020707. doi: 10.1182/bloodadvances.2026020707. Epub ahead of print. PMID: 42349018.
  37. Semenova G, Frank SB, Dumpit R, Han W, Coleman I, Gulati R, Dirican CD, Arman T, Maruwan J, Morrissey C, Haffner MC, Nelson PS, Lee JK. Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. J Clin Invest. 2026 Jun 23:e200438. doi: 10.1172/JCI200438. Epub ahead of print. PMID: 42348027.
  38. Marks JA, Maniar R, Ramchandran KJ, Pietroluongo E, Altan M, Singhal S, Aldea M, Goldman JW, Reiss JW, Wakelee H, Loehrer PJ, Chiara Garassino M, Roden AC, Remon J, Nabel CS, Kim C. Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology. NPJ Precis Oncol. 2026 Jun 26. doi: 10.1038/s41698-026-01574-z. Epub ahead of print. PMID: 42363019.
  39. Okamoto I, Cho BC, Goldberg SB, Goldman JW, de Langen AJ, Piotrowska Z, Riess JW, Yu HA, Garcia Campelo MR, Cetnar J, Kim YJ, Novello S, Shiraishi Y, Ambrose H, Smith PE, Tang KH, Lehman JM, Le X. Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD. Lung Cancer. 2026 Jun 18;218:109501. doi: 10.1016/j.lungcan.2026.109501. Epub ahead of print. PMID: 42361644.
  40. Baxter-King R, Brown JR, Enos RD, Naeim A, Vavreck L. Local partisan context and mental health. Proc Natl Acad Sci U S A. 2026 Jul 7;123(27):e2522718123. doi: 10.1073/pnas.2522718123. Epub 2026 Jun 29. PMID: 42372137.
  41. Girard N, Goldman J, Lu S, Bar J, Horinouchi H, Daaboul N, Liu C, Çiçin I, Katgi N, Zer A, Ciuleanu T, Reinmuth N, Planchard D, Lee SH, Mansfield AS, Moskovitz M, Baijal S, Baik C, Hrom JS, Heist RS, Yazici O, Verma M, Uema D, Patel S, Xia S, Ratajczak C, Camidge DR. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial. JTO Clin Res Rep. 2026 Mar 16;7(7):100988. doi: 10.1016/j.jtocrr.2026.100988. PMID: 42368479; PMCID: PMC13293683.
View the full list of Hematology Oncology publications